Press Release Pharnext Announces PXT3003 for the Treatment of CharcotMarie-Tooth Disease Type 1A has Been Granted Promising Innovative Medicine (PIM) […]
Continue Reading2019.08.30_PXT3003_US_FDA_EN
Continue ReadingCRISPR/Cas9 Treatment Can Improve Nerve Functioning in Mouse Model of CMT1A, Study Suggests
Continue ReadingNantes, France – May 15th, 2019 InFlectis BioScience SAS, a drug discovery company committed to the development of innovative therapeutics […]
Continue Reading
Acceleron Pharma Inc, a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics
Continue ReadingResearch conducted at the Institute of Neurology of University College London (UCL) just published in the Proceedings of the National Academy of Sciences USA has identified a set of novel therapeutic targets for a subtype of Charcot-Marie-Tooth disease (CMT), a human condition that currently has no effective treatments.
Continue ReadingLast Updated: Saturday 24th November, 2018